ISIS 696844

Drug Profile

ISIS 696844

Alternative Names: ISIS-696844

Latest Information Update: 17 Jun 2016

Price : $50

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Age-related macular degeneration

Most Recent Events

  • 25 Mar 2016 Phase-I clinical trials in Age-related macular degeneration (In volunteers) in New Zealand (SC) (ACTRN12616000335493)
  • 25 Mar 2016 Preclinical trials in Age-related macular degeneration in USA (SC) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top